(Q24236545)

8

0 references

Katja Komossa

1

0 references

author name string

Katja Komossa

1

0 references

Heike Hunger

3

0 references

Franziska Schmid

4

0 references

Sandra Schwarz

5

0 references

Lorna Duggan

Cochrane Database of Systematic Reviews

6

0 references

language of work or name

English

0 references

publication date

2010

0 references

published in

0 references

issue

3

0 references

page(s)

CD006654

0 references

cites work

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Bias in meta-analysis detected by a simple, graphical test

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Risperidone versus olanzapine for schizophrenia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Aripiprazole for schizophrenia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Olanzapine for schizophrenia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Measuring inconsistency in meta-analyses

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

A rating scale for drug-induced akathisia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Imputing missing standard deviations in meta-analyses can provide accurate results

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Meta-analyses involving cross-over trials: methodological issues

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Detecting skewness from summary information

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

27 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

27 September 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Standardized remission criteria in schizophrenia.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Schizophrenia and employment - a review

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Issues in the meta-analysis of cluster randomized trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Subjective well-being and quality of life under atypical antipsychotic treatment

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Effects of neuroleptic medications on speech disorganization in schizophrenia: biasing associative networks towards meaning

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Dropout rates in randomised antipsychotic drug trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Statistics notes. Trials randomised in clusters

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Treatment programme and long-term outcome in chronic schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

The unit of analysis error in studies about physicians' patient care behavior

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Revising axis V for DSM-IV: a review of measures of social functioning

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Olanzapine: a novel atypical neuroleptic agent

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

A rating scale for extrapyramidal side effects

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia

30 May 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Early withdrawal in a double-blind randomized clinical trial with olanzapine and risperidone performed in adolescents with first psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Antipsychotic-induced weight gain and therapeutic response: a differential association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Unbalanced statistical analysis of combined divalproex and antipsychotic therapy for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Clinical experience with atypical antipsychotics in an acute inpatient unit: focus on quetiapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

A crossover study on lipid and weight changes associated with olanzapine and risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Community treatment orders: relationship to clinical care, medication compliance, behavioural disturbance and readmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

The influence of olanzapine versus risperidone on facial expression of emotions in schizophrenia--preliminary results of a facial electromyogram study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

What does the PANSS mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Clinical implications of Brief Psychiatric Rating Scale scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Hyperglycemia associated with antipsychotic treatment in a multicenter drug safety project

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

International Multisite Double-Blind Trial of the Atypical Antipsychotics Risperidone and Olanzapine in 175 Elderly Patients With Chronic Schizophrenia

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169107

Double-blind study of clozapine dose response in chronic schizophrenia

29 November 2018

1 reference

12 December 2020

The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia

1 reference

12 December 2020

[The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use]

1 reference

12 December 2020

Suicide in schizophrenics, manics, depressives, and surgical controls. A comparison with general population suicide mortality

1 reference

12 December 2020

Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia

1 reference

12 December 2020

Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison

1 reference

12 December 2020

[Current assessment of new/atypical neuroleptic agents]

1 reference

12 December 2020

Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks

1 reference

12 December 2020

Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: A switch study

1 reference

12 December 2020

A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms

1 reference

12 December 2020

Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes

1 reference

12 December 2020

1 reference

12 December 2020

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

12 December 2020

Olanzapine, sertindole and schizophrenia

1 reference

12 December 2020

Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design

1 reference

12 December 2020

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

12 December 2020

Attenuation of Antipsychotic-Induced Weight Gain With Early Behavioral Intervention in Drug-Naive First-Episode Psychosis Patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006654.PUB2

7 January 2021